Table 1

Baseline and follow-up characteristics of the patients

Baseline1-year follow-up5 years follow-up
Age52 (13.6) n=210
Sex, females, n (%)138 (66%) n=210
Disease duration, days99 (44.8) n=210
IgM RF positivity, n (%)145 (69%) n=210
Anti-CCP positivity, n (%)133 (63%) n=210
Tender joint count, range 0–2811 (7) n=2102 (5)* n=1991 (4)* n=113
Swollen joint count, range 0–289 (6) n=2101 (1)* n=1991 (2)* n=113
VAS-pain, 0–100 mm VAS49.9 (23.9) n=20918.7 (20.7)* n=19815.1 (20.9)* n=109
VAS-PtGlobal, 0–100 mm53.6 (25.6) n=21020.3 (22.4)* n=19821.0 (1–23)* n=109
HAQ, range 0–31.1 (0.7) n=2100.4 (0.5)* n=1990.4 (0.5)* n=110
Serum CRP, mg/L30.1 (33.5) n=20711.2 (15.8)* n=1986.6 (12.7)* n=112
DAS28 score, CRP based5.3 (1.1) n=2072.5 (1.1)* n=1972.1 (1.1)* n=108
Total SvH score5.2 (6.6) n=2046.0 (7.4)* n=20310.3 (13.2)* n=107
Erosive (SvH erosion score>0), n (%)115 (56%) n=204128 (63%) n=20371 (66%) n=107
MRI parameters
 MRI wrist synovitis score, range 0–94.5 (2.4) n=1983.1 (1.9)* n=1862.6 (2.0)* n=92
 MRI wrist tenosynovitis score, range 0–274.1 (4.2) n=1941.4 (2.3)* n=1870.8 (1.9)* n=92
 MRI wrist osteitis score, range 0–452.5 (6.3) n=2071.8 (5.7)* n=1951.3 (3.7) n=94
 MRI wrist erosion score, range 0–1501.7 (2.4) n=2052.2 (2.8)* n=1943.0 (5.5)* n=95
 MRI wrist JSN score, range 0–680.5 (1.3) n=2090.8 (1.5)* n=1951.6 (3.3)* n=94
 MRI wrist combined inflammation score, range 0–8111.2 (10.1) n=1946.4 (7.5)* n=1864.6 (5.7)* n=91
 MRI wrist combined damage score, range 0–2182.2 (3.2) n=2052.9 (3.8)* n=1944.6 (8.6)* n=94
 Erosive wrist (RAMRIS erosion score>0), n (%)127 (62%) n=205130 (67%) n=19472 (76%) n=95
 MRI MCP synovitis score, range 0–124.3 (2.5) n=1782.9 (2.0)* n=1642.3 (2.1)* n=66
 MRI MCP tenosynovitis score, range 0–122.4 (2.5) n=1810.9 (1.7)* n=1640.5 (1.1)* n=66
 MRI MCP osteitis score, range 0–240.3 (1.0) n=1820.2 (0.7)* n=1750.1 (0.4) n=77
 MRI MCP erosion score, range 0–800.8 (1.0) n=1810.9 (1.2) n=1690.9 (1.5)* n=72
 MRI MCP JSN score, range 0–160.1 (0.5) n=1730.1 (0.5)* n=1730.1 (0.4) n=76
 MRI MCP combined inflammation score, range 0–487.0 (4.5) n=1644.0 (3.3)* n=1562.9 (3.0)* n=64
 MRI MCP combined damage score, range 0–960.9 (1.3) n=1581.0 (1.4)* n=1680.9 (1.7)* n=69
 Erosive MCP joints (RAMRIS erosion score<0), n (%)80 (44%) n=18184 (50%) n=16931 (43%) n=72
 MRI total synovitis score, range 0–218.8 (4.1) n=1735.9 (3.0)* n=1624.6 (3.2)* n=66
 MRI total tenosynovitis score, range 0–396.7 (6.0) n=1722.2 (3.6)* n=1631.0 (1.8)* n=66
 MRI total osteitis score, range 0–692.9 (6.7) n=1851.8 (5.4)* n=1780.9 (3.1)* n=77
 MRI total erosion score, range 0–2302.5 (2.8) n=1783.1 (3.3)* n=1694.1 (6.3)* n=72
 MRI total JSN score, range 0–840.6 (1.4) n=1900.9 (1.7)* n=1771.7 (3.6)* n=81
 MRI total combined inflammation score, range 0–12917.9 (12.8) n=1569.7 (8.1)* n=1566.6 (6.3)* n=64
 MRI total combined damage score, range 0–3143.1 (3.7) n=1774.0 (4.3)* n=1695.9 (9.9)* n=69
 Erosive total scores (RAMRIS erosion score>0), n (%)131 (74%) n=178131 (78%) n=16962 (86%) n=72
  • *p<0.05 (Wilcoxon signed-rank test) for comparison to baseline.

  • Mean (SD) scores of clinical, biochemical and MRI data at baseline and after 1-year and 5 years follow-up.

  • CCP, cyclic citrullinated protein; CRP, C reactive protein; DAS, disease activity score; HAQ, health assessment questionnaire; JSN, joint space narrowing; PtGlobal, patient global; RAMRIS, rheumatoid arthritis MRI score; RF, rheumatoid factor;  VAS, visual analogue scale.